CYTK · Cytokinetics Inc · Earnings Call Transcripts & Audio
$66.02
+0.11 (+0.17%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$9.20B
Shares
139.02M
Volume · Oct 1
204.2K
Avg daily vol (3M)
1.92M
Cytokinetics Inc Earnings Call Transcripts
Quarterly earnings calls for Cytokinetics Inc (CYTK), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼53.7%
$2.52M
−$142.31M
'22 Q3
22-11-03
▼96.5%
$1.96M
−$137.38M
'22 Q4
23-03-01
▲301.8%
$4.61M
−$131.29M
'23 Q1
23-05-04
▼99%
$867,000
−$128.64M
'23 Q2
23-08-03
▼85%
$378,000
−$129.42M
'23 Q3
23-11-02
▼14.6%
$1.67M
−$136.90M
'23 Q4
24-02-27
▼81.9%
$835,000
−$135.64M
'24 Q1
24-05-08
▼71.3%
$249,000
−$143.32M
'24 Q2
24-08-08
▲22.5%
$463,000
−$160.54M
'24 Q3
24-09-30
▲912.4%
$16.93M
−$150.02M
'24 Q4
25-02-27
▲89.1%
$1.58M
−$161.38M
'25 Q1
25-05-06
▲26714.9%
$66.77M
−$134.37M
'25 Q2
25-08-07
▲318.1%
$1.94M
−$306.18M
'25 Q3
25-11-05
▲4.9%
$17.75M
−$183.03M
'25 Q4
26-02-24
▲1125.8%
$19.36M
−$206.03M
'26 Q1
26-05-05
LATEST
▼57.1%
$28.62M
−$198.76M
'26 Q2
26-08-06
Conference
Investor event
2026-09-14
Cytokinetics Inc (CYTK) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Cytokinetics Inc (CYTK) Q2 2026 Earnings Call Transcript
Confident tone
Mycorso U.S. commercial launch momentum
Aficampten NHCM label expansion (Acacia-HCM)
Regulatory and FDA interactions (priority review)
Revenue
$28.62M
▼ 57.1% YoY Diluted EPS
$-1.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Cytokinetics Inc (CYTK) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Cytokinetics Inc (CYTK) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Cytokinetics Inc (CYTK) Q1 2026 Earnings Call Transcript
Confident tone
MYCorzo U.S. commercial launch
Acacia HCM Phase 3 results
Financial performance and guidance
Revenue
$19.36M
▲ 1125.8% YoY Diluted EPS
$-1.67
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-04-13
Cytokinetics Inc (CYTK) April 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-11
Cytokinetics Inc (CYTK) March 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-24
Cytokinetics Inc (CYTK) Q4 2025 Earnings Call Transcript
Confident tone
MYCorzo U.S. commercial launch
ACACIA-HCM in non-obstructive HCM
HFpEF pipeline opportunity
Revenue
$17.75M*
▲ 4.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Cytokinetics Inc (CYTK) Q3 2025 Earnings Call Transcript
Confident tone
FDA approval and launch readiness for aficamten
Pipeline programs beyond aficamten
European and global regulatory progress
Revenue
$1.94M
▲ 318.1% YoY Diluted EPS
$-2.55
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Cytokinetics Inc (CYTK) Q2 2025 Earnings Call Transcript
Confident tone
ACACIA-HCM in non-obstructive HCM
FDA regulatory review of aficamten (PDUFA extension)
Heart failure pipeline (omecamtiv mecarbil / ulacamten)
Revenue
$66.77M
▲ 26714.9% YoY Diluted EPS
$-1.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Cytokinetics Inc (CYTK) Q1 2025 Earnings Call Transcript
Positive tone
Aficamten oHCM NDA approval
FDA REMS and PDUFA extension
ACACIA-HCM nHCM pivotal trial
Revenue
$1.58M
▲ 89.1% YoY Diluted EPS
$-1.36
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Transcript
Confident tone
Commercial readiness and U.S. launch
International partnerships
Pipeline diversification
Revenue
$16.93M*
▲ 912.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Cytokinetics Inc (CYTK) Q3 2024 Earnings Call Transcript
Confident tone
Pipeline diversification beyond aficamten
Aficamten NDA submission and FDA review
Earlier-stage pipeline and neuromuscular programs
Revenue
$463,000
▲ 22.5% YoY Diluted EPS
$-1.36
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Cytokinetics Inc (CYTK) Q2 2024 Earnings Call
Revenue
$249,000
▼ 71.3% YoY Diluted EPS
$-1.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Cytokinetics Inc (CYTK) Q1 2024 Earnings Call Transcript
Confident tone
Aficamten pivotal data and presentations
Regulatory submissions and FDA engagement
Commercial readiness for launch
Revenue
$835,000
▼ 81.9% YoY Diluted EPS
$-1.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Cytokinetics Inc (CYTK) Q4 2023 Earnings Call Transcript
Confident tone
SEQUOIA-HCM Phase 3 results
Additional aficamten clinical trials
Pipeline beyond aficamten
Revenue
$1.67M*
▼ 14.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Cytokinetics Inc (CYTK) Q3 2023 Earnings Call Transcript
Revenue
$378,000
▼ 85% YoY Diluted EPS
$-1.35
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Cytokinetics Inc (CYTK) Q2 2023 Earnings Call Transcript
Revenue
$867,000
▼ 99% YoY Diluted EPS
$-1.34
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Cytokinetics Inc (CYTK) Q1 2023 Earnings Call Transcript
Revenue
$4.61M
▲ 301.8% YoY Diluted EPS
$-1.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-01
Cytokinetics Inc (CYTK) Q4 2022 Earnings Call Transcript
Revenue
$1.96M*
▼ 96.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Cytokinetics Inc (CYTK) Q3 2022 Earnings Call Transcript
Revenue
$2.52M
▼ 53.7% YoY Diluted EPS
$-1.52
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Cytokinetics Inc (CYTK) Q2 2022 Earnings Call Transcript
Revenue
$88.97M
▲ 3029.4% YoY Diluted EPS
$-0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Cytokinetics Inc (CYTK) Q1 2022 Earnings Call Transcript
Revenue
$1.15M
▼ 82.5% YoY Diluted EPS
$-1.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Cytokinetics Inc (CYTK) Q4 2021 Earnings Call Transcript
Revenue
$55.60M*
▲ 727.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Cytokinetics Inc (CYTK) Q3 2021 Earnings Call Transcript
Revenue
$5.44M
▼ 87% YoY Diluted EPS
$-0.95
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Cytokinetics Inc (CYTK) Q2 2021 Earnings Call Transcript
Revenue
$2.84M
▼ 20.9% YoY Diluted EPS
$-0.86
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Cytokinetics Inc (CYTK) Q1 2021 Earnings Call Transcript
Revenue
$6.55M
▲ 71.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Cytokinetics Inc (CYTK) Q4 2020 Earnings Call Transcript
Revenue
$6.72M*
▲ 29% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Cytokinetics Inc (CYTK) Q3 2020 Earnings Call Transcript
Revenue
$41.69M
▲ 588.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Cytokinetics Inc (CYTK) Q2 2020 Earnings Call Transcript
Revenue
$3.59M
▼ 49.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-14
Cytokinetics Inc (CYTK) Q1 2020 Earnings Call Transcript
Revenue
$3.83M
▼ 54.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–31 of 31 earnings calls
Key facts
CIK
1061983
CUSIP
23282W605
13F (30d)
13 filings
12 filers
Visit website
Investor relations